Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Influenza

Free Subscription 24.03.2025 7 Am J Med 1 Arch Virol 2 Biochem Biophys Res Commun 2 BMC Pediatr 2 Cell 1 Epidemiol Infect 1 J Exp Med 1 J Immunol 1 J Infect 11 J Infect Dis 8 J Virol 1 PLoS Comput Biol 19 PLoS One 3 Proc Natl Acad Sci U S A 3 Vaccine 2 Virologie (Montrouge) 1 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Med

1. HOLLAND J, Sheehan D, Brown S, O'Flanagan S, et al
   Immune Response and Cognitive Impairment in Post-COVID Syndrome: A Systematic Review.
   Am J Med. 2025;138:698-711.
   PubMed         Abstract available
   
   
2. PASCULLI P, Zingaropoli MA, Dominelli F, Solimini AG, et al
   Insights into Long COVID: Unraveling Risk Factors, Clinical Features, Radiological Findings, Functional Sequelae and Correlations: A Retrospective Cohort Study.
   Am J Med. 2024 Sep 17:S0002-9343(24)00569-2. doi: 10.1016/j.amjmed.2024.
   PubMed         Abstract available
   
   
3. XU J, Wu D, Yang J, Zhao Y, et al
   Adult Outpatients with Long COVID Infected with SARS-CoV-2 Omicron Variant. Part 1: Oral Microbiota Alterations.
   Am J Med. 2025;138:732-741.
   PubMed         Abstract available
   
   
4. YOO KH, Lee SH, Cho Y, Kim YJ, et al
   Synergistic Effect of SARS-CoV-2 Infection and COVID-19 Vaccination on the Risk of Venous Thromboembolism.
   Am J Med. 2025;138:673-680.
   PubMed         Abstract available
   
   
5. MARKSER A, Vockel J, Schneider A, Baumeister-Lingens L, et al
   Non-Invasive Brain Stimulation for Post-COVID-19 Conditions: A Systematic Review.
   Am J Med. 2025;138:681-697.
   PubMed         Abstract available
   
   
6. SAWANO M, Wu Y, Shah RM, Zhou T, et al
   Long COVID Characteristics and Experience: A Descriptive Study From the Yale LISTEN Research Cohort.
   Am J Med. 2025;138:712-720.
   PubMed         Abstract available
   
   
7. SANAL-HAYES NEM, Hayes LD, Mclaughlin M, Berry ECJ, et al
   Post-Traumatic Stress Disorder and Complex Post-Traumatic Stress Disorder in People with Long COVID, ME/CFS, and Controls.
   Am J Med. 2025;138:742-749.
   PubMed         Abstract available
   
   

   
   Arch Virol

8. ZHANG H, Ouyang S, Qu Y, Li Z, et al
   Humoral immune response characteristics of vulnerable populations against SARS-CoV-2 strains EG.5 and JN.1 after infection with strains BA.5 and XBB.
   Arch Virol. 2025;170:82.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

9. GU L, Wang ZJ, Zhang XR, Liu Y, et al
   Targeting the liquid-liquid phase separation of nucleocapsid broadly inhibits the replication of SARS-CoV-2 strains.
   Biochem Biophys Res Commun. 2025;756:151594.
   PubMed         Abstract available
   
   
10. KOCHAROVSKAYA MV, Pichkur EB, Ivannikov AD, Kharlampieva DD, et al
    Structure and dynamics of Alpha B.1.1.7 SARS-CoV-2 S-protein in complex with Fab of neutralizing antibody REGN10987.
    Biochem Biophys Res Commun. 2025;755:151558.
    PubMed         Abstract available
    
    

    
    BMC Pediatr

11. BARIDAH I, Setyowireni DK, Citta AN, Arguni E, et al
    The severity of pediatric COVID-19 during hospitalization is not associated with mortality within six months of discharge.
    BMC Pediatr. 2025;25:199.
    PubMed         Abstract available
    
    
12. POURJOULA F, Mirlohi SH, Ghanbari N
    Comparative analysis of croup severity and treatment in pediatric patient: a study of COVID-19 positive vs. negative cases during peak Omicron.
    BMC Pediatr. 2025;25:194.
    PubMed         Abstract available
    
    

    
    Cell

13. JIANG S, Wu F
    Global surveillance and countermeasures for ACE2-using MERS-related coronaviruses with spillover risk.
    Cell. 2025;188:1465-1468.
    PubMed         Abstract available
    
    
14. CHEN J, Zhang W, Li Y, Liu C, et al
    Bat-infecting merbecovirus HKU5-CoV lineage 2 can use human ACE2 as a cell entry receptor.
    Cell. 2025;188:1729-1742.
    PubMed         Abstract available
    
    

    
    Epidemiol Infect

15. 
    Are children and adolescents living with HIV in Europe and South Africa at higher risk of SARS-CoV-2 and poor COVID-19 outcomes?
    Epidemiol Infect. 2025;153:e44.
    PubMed         Abstract available
    
    

    
    J Exp Med

16. GROEN K, Kuratli R, Enkelmann J, Fernbach S, et al
    Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design.
    J Exp Med. 2025;222:e20242039.
    PubMed         Abstract available
    
    

    
    J Immunol

17. RAO AS, Ugwu N, Onufer AP, Kumova O, et al
    Cathelicidin-related antimicrobial peptide (CRAMP) is toxic during neonatal murine influenza virus infection.
    J Immunol. 2025 Mar 18:vkae053. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Infect

18. ZHAO J, Sheng G, Lyu Y, Sun Y, et al
    Oral ADC189 for Adults and Adolescents with Uncomplicated Influenza.
    J Infect. 2025 Mar 13:106472. doi: 10.1016/j.jinf.2025.106472.
    PubMed         Abstract available
    
    

    
    J Infect Dis

19. WONG JY, Cheung JK, Presanis AM, De Angelis D, et al
    Assessing the impact of influenza epidemics in Hong Kong.
    J Infect Dis. 2025 Mar 19:jiaf140. doi: 10.1093.
    PubMed         Abstract available
    
    
20. QUACH HQ, Goergen KM, Grill DE, Ovsyannikova IG, et al
    IL-8 as a Causal Link Between Aging and Impaired Influenza Antibody Responses in Older Adults.
    J Infect Dis. 2025 Mar 17:jiaf148. doi: 10.1093.
    PubMed         Abstract available
    
    
21. WANG J, Genberg BL, Feder K, Kirk GD, et al
    Impact of pandemic-induced service disruptions and behavioral changes on HCV and HIV transmission amongst people who inject drugs: a modeling study.
    J Infect Dis. 2024 Dec 6:jiae599. doi: 10.1093.
    PubMed         Abstract available
    
    
22. MENG Y, Lin Y, Xiong W, Lau EHY, et al
    Effective Real-time Transmission Estimations Incorporating Population Viral Load Distributions Amid SARS-CoV-2 Variants and Preexisting Immunity.
    J Infect Dis. 2025;231:684-691.
    PubMed         Abstract available
    
    
23. MADHI SA, Simoes EAF, Acevedo A, Novoa Pizarro JM, et al
    A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
    J Infect Dis. 2025;231:e478-e487.
    PubMed         Abstract available
    
    
24. THAMBI N, Phuah JY, Staupe RP, Tobias LM, et al
    Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150.
    J Infect Dis. 2025;231:e488-e496.
    PubMed         Abstract available
    
    
25. PROBOSTE T, Bista D, Clark NJ, Arora S, et al
    Ascertainment of Community Exposure Sites to Ross River Virus During the 2020 Outbreak in Brisbane, Australia.
    J Infect Dis. 2025;231:e501-e510.
    PubMed         Abstract available
    
    
26. MAK J, Khan S, Britton A, Rose S, et al
    Association of mRNA COVID-19 vaccination and reductions in Post-COVID Conditions following SARS-CoV-2 infection in a US prospective cohort of essential workers.
    J Infect Dis. 2024 Nov 13:jiae556. doi: 10.1093.
    PubMed         Abstract available
    
    
27. WINKEL AMAM, Kozanli E, Haverkort ME, Euser SM, et al
    Lower Levels of Household Transmission of SARS-CoV-2 Omicron Variant of Concern vs Wild Type: An Interplay Between Transmissibility and Immune Status.
    J Infect Dis. 2025;231:653-664.
    PubMed         Abstract available
    
    
28. REILLY C, Mylonakis E, Dewar R, Young B, et al
    Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019.
    J Infect Dis. 2025;231:677-683.
    PubMed         Abstract available
    
    
29. MONTO AS, Foster-Tucker JE, Callear AP, Leis AM, et al
    Respiratory Viral Infections From 2015 to 2022 in the HIVE Cohort of American Households: Incidence, Illness Characteristics, and Seasonality.
    J Infect Dis. 2025;231:795-804.
    PubMed         Abstract available
    
    

    
    J Virol

30. FURUSAWA Y, Kiso M, Uraki R, Sakai-Tagawa Y, et al
    Amino acid substitutions in NSP6 and NSP13 of SARS-CoV-2 contribute to superior virus growth at low temperatures.
    J Virol. 2025 Feb 12:e0221724. doi: 10.1128/jvi.02217.
    PubMed         Abstract available
    
    
31. KUHN AJ, Outlaw VK, Marcink TC, Yu Z, et al
    Enhancing the solubility of SARS-CoV-2 inhibitors to increase future prospects for clinical development.
    J Virol. 2025 Feb 4:e0215924. doi: 10.1128/jvi.02159.
    PubMed         Abstract available
    
    
32. PHAN T, Ribeiro RM, Edelstein GE, Boucau J, et al
    Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance.
    J Virol. 2025 Feb 4:e0162324. doi: 10.1128/jvi.01623.
    PubMed         Abstract available
    
    
33. SAMAAN P, Korosec CS, Budylowski P, Chau SLL, et al
    mRNA vaccine-induced SARS-CoV-2 spike-specific IFN-gamma and IL-2 T-cell responses are predictive of serological neutralization and are transiently enhanced by pre-existing cross-reactive immunity.
    J Virol. 2025 Jan 31:e0168524. doi: 10.1128/jvi.01685.
    PubMed         Abstract available
    
    
34. WANG X, Dong M, Wu X, Schnepf D, et al
    Single-cell transcriptomics reveals a compartmentalized antiviral interferon response in the nasal epithelium of mice.
    J Virol. 2025 Feb 4:e0141324. doi: 10.1128/jvi.01413.
    PubMed         Abstract available
    
    
35. MA R, Zhang X, Li R, Dong X, et al
    PLSCR1 suppresses SARS-CoV-2 infection by downregulating cell surface ACE2.
    J Virol. 2025 Feb 13:e0208524. doi: 10.1128/jvi.02085.
    PubMed         Abstract available
    
    
36. BEAVIS AC, Li Z, Briggs K, Gingerich MC, et al
    Efficacy of parainfluenza virus 5 (PIV5)-vectored intranasal COVID-19 vaccine as a single dose primer and booster against SARS-CoV-2 variants.
    J Virol. 2025 Mar 21:e0198924. doi: 10.1128/jvi.01989.
    PubMed         Abstract available
    
    
37. BEAVIS AC, Xiao P, Gingerich MC, Briggs K, et al
    A parainfluenza virus 5 (PIV5)-vectored intranasal SARS-CoV-2 vaccine (CVXGA1) elicits protective and long-lasting immunity in nonhuman primates.
    J Virol. 2025 Mar 21:e0199024. doi: 10.1128/jvi.01990.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

38. EALES O, Shearer FM, McCaw JM
    How immunity shapes the long-term dynamics of influenza H3N2.
    PLoS Comput Biol. 2025;21:e1012893.
    PubMed         Abstract available
    
    

    
    PLoS One

39. BAAKLINY M, Ghosn N, Saleh N, Maison P, et al
    Effectiveness of the Pfizer-BioNTech (BNT162b2) vaccine against the omicron variant of SARS-CoV-2 among adults aged 50 and above: A case-control study in Lebanon, June 2022.
    PLoS One. 2025;20:e0318344.
    PubMed         Abstract available
    
    
40. VICENCIO VV, Viengkham C, Grange N, Norton S, et al
    COVID-19 outbreak management in Western Sydney residential aged care homes: A mixed-methods Donabedian evaluation.
    PLoS One. 2025;20:e0318490.
    PubMed         Abstract available
    
    
41. PHIRI MM, Dunkley Y, Di Giacomo E, Lora W, et al
    Factors influencing uptake of COVID-19 diagnostics in Sub-Saharan Africa: a rapid scoping review.
    PLoS One. 2025;20:e0305512.
    PubMed         Abstract available
    
    
42. STRINGER WS, Labar AS, Geleris JD, Sholle EV, et al
    Three hospitalized non-critical COVID-19 subphenotypes and change in intubation or death over time: A latent class analysis with external and longitudinal validation.
    PLoS One. 2025;20:e0316434.
    PubMed         Abstract available
    
    
43. SUWANAI H, Kanda M, Harada K, Ishii K, et al
    Diabetes with COVID-19 was a significant risk factor for mortality, mechanical ventilation, and renal replacement therapies: A multicenter retrospective study in Japan.
    PLoS One. 2025;20:e0319801.
    PubMed         Abstract available
    
    
44. MIRANDA AR, Scotta AV, Cortez MV, Soria EA, et al
    Two-years mothering into the pandemic: Impact of the three COVID-19 waves in the Argentinian postpartum women's mental health.
    PLoS One. 2025;20:e0294220.
    PubMed         Abstract available
    
    
45. PADILLA S, Andreo M, Marco P, Marco-Rico A, et al
    Enhanced prediction of thrombotic events in hospitalized COVID-19 patients with soluble thrombomodulin.
    PLoS One. 2025;20:e0319666.
    PubMed         Abstract available
    
    
46. HO T, Lailo JM, Ramoran E, Mutreja K, et al
    Leveraging a digital network of pharmacy professionals to test a technology-assisted model to improve pharmacy access to quality-assured COVID-19 rapid antigen tests approved for self-use in Vietnam.
    PLoS One. 2025;20:e0318331.
    PubMed         Abstract available
    
    
47. CARDOSO CO, Rodrigues Sandoval ES, de Oliveira Chagas LBM, Badra SJ, et al
    Neurologic manifestations of COVID-19 and viral test in cerebrospinal fluid.
    PLoS One. 2025;20:e0312621.
    PubMed         Abstract available
    
    
48. TAYLOR-ABDULAI HB, Dzantor EK, Mensah NK, Asumah MN, et al
    Coronavirus disease 2019 (COVID-19) vaccine acceptability in Ghana: An urban-based population study.
    PLoS One. 2025;20:e0319798.
    PubMed         Abstract available
    
    
49. MALTESE C, Gandhi CK, Ramirez SI, Sznajder KK, et al
    Access to lactation consult services during the COVID-19 pandemic and the impact on breastfeeding outcome variables.
    PLoS One. 2025;20:e0318749.
    PubMed         Abstract available
    
    
50. HAMADANI JD, Bhuiyan SA, Hasan MI, Grantham-McGregor S, et al
    The effect of exposure to the COVID-19 pandemic on nutritional status and cognitive, motor, and behavioural development among children aged 20 months in rural Bangladesh: A repeated cross-section study between 2020 and 2022.
    PLoS One. 2025;20:e0309836.
    PubMed         Abstract available
    
    
51. MUHAMAD NA, Ma'amor NH, Jamalluddin NH, Rosli IA, et al
    Technostress and its associated factors: Burnout and fatigue among Malaysian healthcare workers (HCWs) in state hospitals.
    PLoS One. 2025;20:e0319506.
    PubMed         Abstract available
    
    
52. PEREIRA AMM, Esperidiao MA, Andrade SKAV, Silva JFM, et al
    Governance and responses of health and surveillance systems to COVID-19 in BRICS countries: A scoping review protocol.
    PLoS One. 2025;20:e0319572.
    PubMed         Abstract available
    
    
53. GU Z, Luo X, Sun R, Xi T, et al
    Long-term effects of the COVID-19 lockdown on the structural and functional outcomes of neovascular AMD patients in Suzhou, China.
    PLoS One. 2025;20:e0319677.
    PubMed         Abstract available
    
    
54. AGHA S, Nazir S, Kaleem M, Najeeb F, et al
    Performance evaluation of reduced complexity deep neural networks.
    PLoS One. 2025;20:e0319859.
    PubMed         Abstract available
    
    
55. HARUN SNF, Jasman N, Mustapha F, Jaafar N, et al
    Noteworthy trends in maladaptive coping strategies and hindrances to help-seeking behaviour among adolescents living in Malaysia's People's Housing Project (PPR) during the COVID-19 pandemic: A qualitative study.
    PLoS One. 2025;20:e0318381.
    PubMed         Abstract available
    
    
56. GRANADOS SAMAYOA JA, Moore CA, Ruisch BC, Ladanyi JT, et al
    Is there anything good about conspiracy beliefs? Belief in COVID-19 conspiracy theories is associated with benefits to well-being.
    PLoS One. 2025;20:e0319896.
    PubMed         Abstract available
    
    
57. OUAKOUAK ML, Ouedraogo N, Hewapathirana GI, Zaitouni M, et al
    Role of leaders' positive mindset in mitigating the effects of crises on organizations: The case of Canadian organizations.
    PLoS One. 2025;20:e0319931.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

58. DOS S P ANDRADE AC, Lacasse E, Dubuc I, Gudimard L, et al
    Deficiency in platelet 12-lipoxygenase exacerbates inflammation and disease severity during SARS-CoV-2 infection.
    Proc Natl Acad Sci U S A. 2025;122:e2420441122.
    PubMed         Abstract available
    
    
59. EILERSEN A, Bjornstad ON, Li R, Schreiber SJ, et al
    Epidemic evolutionarily stable strategies within an age-structured host population.
    Proc Natl Acad Sci U S A. 2025;122:e2418170122.
    PubMed         Abstract available
    
    
60. GAILLETON R, Mathew NR, Reusch L, Schon K, et al
    Ectopic germinal centers in the nasal turbinates contribute to B cell immunity to intranasal viral infection and vaccination.
    Proc Natl Acad Sci U S A. 2025;122:e2421724122.
    PubMed         Abstract available
    
    

    
    Vaccine

61. PATTHAMMAVONG C, Wodniak N, Phounphenghack K, Tengbriacheu C, et al
    Factors associated with influenza and COVID-19 vaccination among health workers in Lao PDR, 2023.
    Vaccine. 2025;54:127006.
    PubMed         Abstract available
    
    
62. HEGMANN TE, Walter EB, Smith MJ, Campbell J, et al
    A phase I study of the safety, reactogenicity and immunogenicity of two quadrivalent seasonal influenza vaccines (Fluzone(R) or Flublok(R)) with or without one of two adjuvants (AF03 or Advax-CpG55.2) in healthy adults 18-45 years of age.
    Vaccine. 2025;54:126991.
    PubMed         Abstract available
    
    
63. THORS V, Vias RD, Bjornsdottir K, Palsdottir EB, et al
    Influenza vaccine effectiveness in Iceland 2014-2022: A test-negative design.
    Vaccine. 2025;55:126981.
    PubMed         Abstract available
    
    

    
    Virologie (Montrouge)

64. CAVARELLI M
    Ghosts of the virus : unmasking the persistent threat of SARS-CoV-2 in Long COVID.
    Virologie (Montrouge). 2025;29:57-68.
    PubMed         Abstract available
    
    
65. CAVARELLI M
    [Ghosts of the virus : unmasking the persistent threat of SARS-CoV-2 in Long COVID].
    Virologie (Montrouge). 2025;29:41-53.
    PubMed         Abstract available
    
    

    
    Virology

66. BENLARBI M, Kenfack DD, Dionne K, Cote-Chenette M, et al
    Longitudinal humoral immunity against SARS-CoV-2 Spike following infection in individuals from Cameroon.
    Virology. 2025;605:110467.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.